LeMaitre Vascular Inc (LMAT) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its position in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) by 2.8% in the third quarter, Holdings Channel reports. The fund owned 995,747 shares of the medical instruments supplier’s stock after acquiring an additional 27,515 shares during the period. Dimensional Fund Advisors LP owned 0.05% of LeMaitre Vascular worth $37,261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in LMAT. BNP Paribas Arbitrage SA raised its position in shares of LeMaitre Vascular by 11,612.5% during the second quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 3,716 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in shares of LeMaitre Vascular during the second quarter valued at about $137,000. Victory Capital Management Inc. raised its position in shares of LeMaitre Vascular by 181.2% during the third quarter. Victory Capital Management Inc. now owns 4,139 shares of the medical instruments supplier’s stock valued at $155,000 after buying an additional 2,667 shares during the last quarter. Royce & Associates LP acquired a new position in shares of LeMaitre Vascular during the second quarter valued at about $156,000. Finally, Royal Bank of Canada raised its position in shares of LeMaitre Vascular by 856.5% during the second quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock valued at $157,000 after buying an additional 4,505 shares during the last quarter. 69.24% of the stock is owned by institutional investors and hedge funds.

LMAT has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Thursday, December 28th. Canaccord Genuity reaffirmed a “hold” rating and set a $30.00 price objective on shares of LeMaitre Vascular in a research report on Monday, October 9th. BidaskClub lowered shares of LeMaitre Vascular from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 27th. First Analysis lowered shares of LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 price objective for the company. in a research report on Friday, October 27th. Finally, Benchmark lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the stock. LeMaitre Vascular presently has an average rating of “Hold” and an average price target of $32.20.

In related news, insider David B. Roberts sold 4,123 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $32.14, for a total value of $132,513.22. Following the sale, the insider now owns 24,482 shares of the company’s stock, valued at $786,851.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 23.70% of the company’s stock.

Shares of LeMaitre Vascular Inc (NASDAQ:LMAT) opened at $32.64 on Friday. The firm has a market cap of $620.91, a PE ratio of 41.85, a P/E/G ratio of 2.36 and a beta of 0.54. LeMaitre Vascular Inc has a 52 week low of $19.82 and a 52 week high of $39.88.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.05. The business had revenue of $24.80 million for the quarter, compared to analysts’ expectations of $25.49 million. LeMaitre Vascular had a net margin of 15.81% and a return on equity of 16.16%. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.17 earnings per share. equities analysts anticipate that LeMaitre Vascular Inc will post 0.84 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2018/01/13/lemaitre-vascular-inc-lmat-shares-bought-by-dimensional-fund-advisors-lp.html.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit